Karyopharm Therapeutics (NASDAQ:KPTI) has been assigned a $18.00 target price by analysts at Cantor Fitzgerald in a note issued to investors on Thursday, March 15th. The brokerage presently has a “buy” rating on the stock. Cantor Fitzgerald’s price target suggests a potential upside of 44.23% from the company’s current price.
KPTI has been the topic of several other research reports. Royal Bank of Canada reaffirmed a “buy” rating and issued a $22.00 price target on shares of Karyopharm Therapeutics in a research report on Friday, March 2nd. assumed coverage on shares of Karyopharm Therapeutics in a research report on Wednesday, November 15th. They issued a “buy” rating and a $23.00 price target on the stock. BidaskClub raised shares of Karyopharm Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, March 8th. HC Wainwright reissued a “buy” rating and set a $23.00 target price on shares of Karyopharm Therapeutics in a research report on Tuesday, December 12th. Finally, ValuEngine cut shares of Karyopharm Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Wednesday, December 6th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and nine have given a buy rating to the company’s stock. Karyopharm Therapeutics has a consensus rating of “Buy” and a consensus target price of $20.10.
Shares of KPTI stock traded down $0.52 on Thursday, reaching $12.48. 500,935 shares of the company were exchanged, compared to its average volume of 500,979. The stock has a market capitalization of $645.49, a PE ratio of -4.44 and a beta of 3.61. Karyopharm Therapeutics has a one year low of $7.48 and a one year high of $18.00.
Karyopharm Therapeutics (NASDAQ:KPTI) last released its quarterly earnings data on Thursday, March 15th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.66) by ($0.14). The firm had revenue of $1.53 million for the quarter, compared to the consensus estimate of $2.26 million. During the same quarter in the previous year, the business earned ($0.65) earnings per share. Karyopharm Therapeutics’s quarterly revenue was up 3163.8% on a year-over-year basis. research analysts forecast that Karyopharm Therapeutics will post -2.83 EPS for the current year.
In related news, CEO Michael Kauffman sold 10,000 shares of Karyopharm Therapeutics stock in a transaction that occurred on Thursday, January 18th. The shares were sold at an average price of $10.09, for a total value of $100,900.00. Following the completion of the transaction, the chief executive officer now directly owns 522,143 shares in the company, valued at approximately $5,268,422.87. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Christopher Brett Primiano sold 2,500 shares of Karyopharm Therapeutics stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $15.01, for a total transaction of $37,525.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 69,000 shares of company stock valued at $928,625. 14.71% of the stock is currently owned by company insiders.
A number of large investors have recently made changes to their positions in KPTI. Vanguard Group Inc. boosted its holdings in Karyopharm Therapeutics by 31.1% in the 2nd quarter. Vanguard Group Inc. now owns 1,621,420 shares of the company’s stock valued at $14,675,000 after purchasing an additional 384,658 shares during the period. JPMorgan Chase & Co. lifted its holdings in shares of Karyopharm Therapeutics by 753.5% during the 3rd quarter. JPMorgan Chase & Co. now owns 307,200 shares of the company’s stock worth $3,342,000 after acquiring an additional 271,208 shares during the last quarter. Franklin Resources Inc. lifted its holdings in shares of Karyopharm Therapeutics by 6.4% during the 4th quarter. Franklin Resources Inc. now owns 3,337,569 shares of the company’s stock worth $32,041,000 after acquiring an additional 200,310 shares during the last quarter. Northern Trust Corp lifted its holdings in shares of Karyopharm Therapeutics by 36.5% during the 2nd quarter. Northern Trust Corp now owns 405,374 shares of the company’s stock worth $3,668,000 after acquiring an additional 108,369 shares during the last quarter. Finally, Iguana Healthcare Management LLC lifted its holdings in shares of Karyopharm Therapeutics by 33.3% during the 3rd quarter. Iguana Healthcare Management LLC now owns 400,000 shares of the company’s stock worth $4,392,000 after acquiring an additional 100,000 shares during the last quarter. 62.45% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: “Karyopharm Therapeutics (NASDAQ:KPTI) Given a $18.00 Price Target by Cantor Fitzgerald Analysts” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece on another site, it was illegally stolen and reposted in violation of international copyright and trademark law. The legal version of this piece can be viewed at https://www.dispatchtribunal.com/2018/04/07/karyopharm-therapeutics-kpti-given-a-18-00-price-target-by-cantor-fitzgerald-analysts.html.
Karyopharm Therapeutics Company Profile
Karyopharm Therapeutics Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor(KPT-330), which is in Phase 2b clinical study in treatments of refractory multiple myeloma; Phase 1b/2 clinical study in combination with backbone treatments for multiple myeloma patients; Phase 2b clinical study in diffuse large B-cell lymphoma; Phase 3 clinical trial in combination with Velcade (bortezomib) and dexamethasone for multiple myeloma patients; and Phase 2/3 clinical study in liposarcoma.
Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.